Posted On: 04/30/2014 6:08:51 AM
Post# of 273256
Celgene Corp (CELG) 146.70 $CELG
Earnings Roundup: Celgene's Rock-Solid Quarter Offers Opportunity
Todd Campbell, The Motley Fool - Motley Fool - Tue Apr 29, 5:30PM CDT
Celgene is one of the most prolific deal makers in the biotech industry, inking dozens of collaborations with emerging biotechs working on the next big thing in medicine. Celgene's collaborations aim to expand upon an already-impressive...
Final Glance: Biotechnology companies
AP - Tue Apr 29, 5:02PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies were up at the close of trading:
Celgene Deal Chief Calls Big Pharma Gutless For Lack of Biotech M&A
at The Street - Tue Apr 29, 3:26PM CDT
Some sharp opinions expressed by healthcare deal-makers at the Allicense 2014 conference.
Midday Glance: Biotechnology companies
AP - Tue Apr 29, 12:19PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are up at 1 p.m.:
Early Glance: Biotechnology companies
AP - Tue Apr 29, 9:30AM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 10 a.m.:
Could Celgene Beat the Biotech Slide?
Cory Renauer, The Motley Fool - Motley Fool - Mon Apr 28, 5:30PM CDT
Last Thursday, Celgene 's first quarter earnings call left the market with mixed emotions. Adjusted earnings per share of $1.67 beat estimates by just $0.02. Revenue grew 18.5% on year to $1.73 billion, $40 million less than the Street was...
Why Gilead Sciences (GILD) Stock Is Up Today
at The Street - Mon Apr 28, 10:16AM CDT
Shares of Gilead Sciences (GILD) are higher today after it was reported that the biopharmaceutical company had a nine day winning streak end last week but it continues to outperform other big biotech stocks like Amgen (AMGN), Celgene (CELG) and...
Biotech M&A is MIA
at The Street - Mon Apr 28, 6:29AM CDT
Healthcare M&A activity is booming but expensive, risky biotech stocks are left on the sidelines.
Tweet of the Week: Drugmakers Can't Get a Second Drug Approved
Brian Orelli, The Motley Fool - Motley Fool - Sun Apr 27, 1:00PM CDT
This week's tweet of the week comes from Frank David, who points out a fact he learned in an article by Matthew Herper: Over half of companies that got a drug approved by the FDA from 1950 to 2011 did so only once. In the following video, senior...
Will This Analyst Upgrade Help Celgene (CELG) Stock Today?
at The Street - Fri Apr 25, 8:33AM CDT
Piper Jaffray upgraded Celgene (CELG) to "overweight" from "neutral" and set a $170 price target. The firm cited valuation, as the stock has lagged over the past couple of months.
Celgene Corporation to Present at Investor Conferences in May
Business Wire - Fri Apr 25, 7:30AM CDT
Celgene Corporation (NASDAQ:CELG) announced that Celgene management will provide an overview of the Company at four upcoming investor conferences in the month of May. The conferences will be webcast live and a link to the webcasts will be available in the Investor Relations section of the Company's website at www.celgene.com.
Drug Approvals, Quarterly Earnings Releases, and Stock Price Updates - Analyst Notes on Merck, Johnson & Johnson, UnitedHealth, Celgene and GW
PR Newswire - Fri Apr 25, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Merck & Co. Inc. (NYSE: MRK), Johnson & Johnson (NYSE: JNJ), UnitedHealth Group Inc. (NYSE: UNH), Celgene Corporation (NASDAQ: CELG) and GW Pharmaceuticals PLC (NASDAQ: GWPH). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/1613-100free.
Upgrade Alert for Celgene (CELG)
Comtex SmarTrend(R) - Fri Apr 25, 6:59AM CDT
Celgene (NASDAQ:CELG) was upgraded from Neutral to Overweight at Piper Jaffray today. The stock closed yesterday at $141.25 on volume of 4.4 million shares, above average daily volume of 4.3 million. Potential upside of 37.1% exists for Celgene, based on a current level of $141.25 and analysts' average consensus price target of $193.60. Celgene shares should first meet resistance at the 50-day moving average (MA) of $150.91 and find additional resistance at the 200-day MA of $152.22.
'Mad Money' Lightning Round: United Rentals Is Really Good
at The Street - Fri Apr 25, 5:00AM CDT
Cramer prefers HollyFrontier to CVR Refining and says wait a bit on GW Pharmaceuticals.
Jim Cramer's 'Mad Money' Recap: Nerds Rule
at The Street - Thu Apr 24, 7:19PM CDT
Uncool companies left for dead last quarter are making a comeback, Cramer says.
Earnings Roundup: Celgene's Rock-Solid Quarter Offers Opportunity
Todd Campbell, The Motley Fool - Motley Fool - Tue Apr 29, 5:30PM CDT
Celgene is one of the most prolific deal makers in the biotech industry, inking dozens of collaborations with emerging biotechs working on the next big thing in medicine. Celgene's collaborations aim to expand upon an already-impressive...
Final Glance: Biotechnology companies
AP - Tue Apr 29, 5:02PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies were up at the close of trading:
Celgene Deal Chief Calls Big Pharma Gutless For Lack of Biotech M&A
at The Street - Tue Apr 29, 3:26PM CDT
Some sharp opinions expressed by healthcare deal-makers at the Allicense 2014 conference.
Midday Glance: Biotechnology companies
AP - Tue Apr 29, 12:19PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are up at 1 p.m.:
Early Glance: Biotechnology companies
AP - Tue Apr 29, 9:30AM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 10 a.m.:
Could Celgene Beat the Biotech Slide?
Cory Renauer, The Motley Fool - Motley Fool - Mon Apr 28, 5:30PM CDT
Last Thursday, Celgene 's first quarter earnings call left the market with mixed emotions. Adjusted earnings per share of $1.67 beat estimates by just $0.02. Revenue grew 18.5% on year to $1.73 billion, $40 million less than the Street was...
Why Gilead Sciences (GILD) Stock Is Up Today
at The Street - Mon Apr 28, 10:16AM CDT
Shares of Gilead Sciences (GILD) are higher today after it was reported that the biopharmaceutical company had a nine day winning streak end last week but it continues to outperform other big biotech stocks like Amgen (AMGN), Celgene (CELG) and...
Biotech M&A is MIA
at The Street - Mon Apr 28, 6:29AM CDT
Healthcare M&A activity is booming but expensive, risky biotech stocks are left on the sidelines.
Tweet of the Week: Drugmakers Can't Get a Second Drug Approved
Brian Orelli, The Motley Fool - Motley Fool - Sun Apr 27, 1:00PM CDT
This week's tweet of the week comes from Frank David, who points out a fact he learned in an article by Matthew Herper: Over half of companies that got a drug approved by the FDA from 1950 to 2011 did so only once. In the following video, senior...
Will This Analyst Upgrade Help Celgene (CELG) Stock Today?
at The Street - Fri Apr 25, 8:33AM CDT
Piper Jaffray upgraded Celgene (CELG) to "overweight" from "neutral" and set a $170 price target. The firm cited valuation, as the stock has lagged over the past couple of months.
Celgene Corporation to Present at Investor Conferences in May
Business Wire - Fri Apr 25, 7:30AM CDT
Celgene Corporation (NASDAQ:CELG) announced that Celgene management will provide an overview of the Company at four upcoming investor conferences in the month of May. The conferences will be webcast live and a link to the webcasts will be available in the Investor Relations section of the Company's website at www.celgene.com.
Drug Approvals, Quarterly Earnings Releases, and Stock Price Updates - Analyst Notes on Merck, Johnson & Johnson, UnitedHealth, Celgene and GW
PR Newswire - Fri Apr 25, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Merck & Co. Inc. (NYSE: MRK), Johnson & Johnson (NYSE: JNJ), UnitedHealth Group Inc. (NYSE: UNH), Celgene Corporation (NASDAQ: CELG) and GW Pharmaceuticals PLC (NASDAQ: GWPH). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/1613-100free.
Upgrade Alert for Celgene (CELG)
Comtex SmarTrend(R) - Fri Apr 25, 6:59AM CDT
Celgene (NASDAQ:CELG) was upgraded from Neutral to Overweight at Piper Jaffray today. The stock closed yesterday at $141.25 on volume of 4.4 million shares, above average daily volume of 4.3 million. Potential upside of 37.1% exists for Celgene, based on a current level of $141.25 and analysts' average consensus price target of $193.60. Celgene shares should first meet resistance at the 50-day moving average (MA) of $150.91 and find additional resistance at the 200-day MA of $152.22.
'Mad Money' Lightning Round: United Rentals Is Really Good
at The Street - Fri Apr 25, 5:00AM CDT
Cramer prefers HollyFrontier to CVR Refining and says wait a bit on GW Pharmaceuticals.
Jim Cramer's 'Mad Money' Recap: Nerds Rule
at The Street - Thu Apr 24, 7:19PM CDT
Uncool companies left for dead last quarter are making a comeback, Cramer says.
(0)
(0)Scroll down for more posts ▼
